Opto Circuits’ arm receives CE Mark approval for 'MiStent SES'

18 Jun 2013 Evaluate

Eurocor Gmbh, a group company of Opto Circuits (India), and its partner Micell Technologies, Inc. received CE (Conformite Europeenne) Mark approval for its MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES) introducing a thin-strut stent that features elimination of the coating from the stent in 45-60 days and the complete absorption of the polymer coating within 90 days.

The MiStent SES is unique in providing local drug delivery both during and after the period of polymer absorption, thereby eliminating long-term polymer exposure, a potential cause of delayed healing and late adverse events. The MiStent SES approval is supported by in-depth clinical analysis from the DESSOLVE I and DESSOLVE II clinical trials. With this CE Mark approval, Micell is preparing to make the MiStent SES commercially available in Europe and other markets where CE Mark approval can expedite the registration process.

Opto Circuits India is a multinational medical device company headquartered out of Bengaluru, India. The company designs, develop, manufacture, market and distribute a range of medical products that are used by healthcare establishments in more than 150 countries.

Opto Circuits (I) Share Price

1.78 0.00 (0.00%)
23-May-2022 18:01 View Price Chart
Peers
Company Name CMP
Poly Medicure 2581.85
Hemant Surgical Inds 136.50
Nureca Ltd. 273.50
Prevest Denpro 540.00
Centenial Surgical 125.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.